| Risk | Moderately High |
|---|---|
| Min SIP Amount | Not Supported |
| Expense Ratio | 0.15% |
| NAV | ₹10.15 (18 Sep 2020) |
|---|---|
| Fund Started | 13 Jul 2018 |
| Fund Size | ₹263 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Reliance Industries Ltd. | Energy | Equity | 9.4% |
| HDFC Bank Ltd. | Financial | Equity | 6.4% |
| ICICI Bank Ltd. | Financial | Equity | 6.0% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 4.1% |
| Hindustan Unilever Ltd. | FMCG | Equity | 4.0% |
| Procter & Gamble Health Ltd. | Healthcare | Equity | 3.6% |
| MRF Ltd. | Automobile | Equity | 3.4% |
| Kotak Mahindra Bank Ltd. | Financial | Equity | 3.1% |
| Gujarat Gas Ltd. | Chemicals | Equity | 2.9% |
| ITC Ltd. | FMCG | Equity | 2.7% |
Tata Value Fund Series 2 Direct Growth is a Equity Mutual Fund Scheme launched by Tata Mutual Fund. This scheme was made available to investors on 13 Jul 2018. null is the Current Fund Manager of Tata Value Fund Series 2 Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹263 Cr and the Latest NAV as of 18 Sep 2020 is ₹10.15.
The Tata Value Fund Series 2 Direct Growth is rated Moderately High risk. Minimum SIP Investment is set to 500.
The Scheme seeks to provide capital appreciation over the tenure of the fund through a diversified equity portfolio following value investment strategy.